Focal Therapy

with Fusion-Guided
Laser Ablation

Precise Treatment. Precise Results.

Focal laser ablation provides a minimally invasive treatment that targets and ablates (destroys) only specific parts of glands, organs, or other tissue needing treatment, while preserving the surrounding and remaining tissue. This generally produces faster recovery, fewer side effects, and less pain and discomfort for patients that may not be good candidates or are inoperable for traditional open surgery*.

About CLS

CLS AB is an innovative medical device company within healthcare technology and therapy. With people in mind, we are at the forefront of developing more precise, more effective interventional healthcare solutions. 

Our TRANBERG™ systems marketed in the US by CLS Americas provide minimally invasive alternatives to traditional treatments and are FDA 510(k) cleared.


Focal therapy using TRANBERG™ Thermal Therapy System

Focal therapy using laser ablation is a growing treatment option for patients with prostate cancer. It is an effective method that treats the tumor locally, saving healthy tissue.

Patient Focused

  • Minimally invasive outpatient procedure.
  • Performed in office, ASC, or hospital.
  • Low risk of complications.
  • Reduced risk of erectile dysfunction and urinary incontinence.
  • Quick procedure – quick recovery. 

A precisely controlled, image-guided laser ablation system for successful Focal Therapy

Our driving force is to design and develop tools for treatment of severe diseases, such as cancer, in a precise and careful way. It is from this perspective we have developed the TRANBERG™ Thermal Therapy System for image-guided focal laser ablation.

  • Precise positioning of the laser applicator in the defined target area using image-guidance.
  • Accurate temperature monitoring and control.
  • Option to choose between transperineal and transrectal pathway access.
  • Targeted tissue destruction.
  • Surrounding, non-cancerous tissue is spared.

How it all started

Through research by our co-founder, professor Karl-Göran Tranberg, CLS has gained significant knowledge and experience with treating/killing cancer tumors using laser ablation under image guidance. 

Today, our TRANBERG™ Thermal Therapy System is optimized for minimally invasive focal therapy of soft tissue and used to treat patients with localized prostate cancer. 

Michael Magnani, President of CLS Americas, about our history
and the TRANBERG products

Play Video

News and insights

5 May, 2023

CLS Americas and Unio Health Partners Announce Clinical Study

We are happy to share that CLS Americas has entered into an agreement with Genesis Research, LLC, an affiliate of Unio Health Partners, to conduct a Phase I clinical study titled, “Micro Ultra-Sound Guided, Transperineal Focal Laser Ablation of Low-to-Intermediate Risk Prostate Cancer.”

Read more
13 April, 2023

CLS Americas Announces Research Collaboration with the National Institutes of Health Clinical Center

Under the agreement, NIHCC will access the clinical utility of the CLS’s TRANBERG® Thermal Therapy System towards MRI/Ultrasound fusion-guided focal laser ablation (FLA) of prostate tissue and prostate cancer in male patients.

Read more
21 March, 2023

NEW: Animation showing Fusion-guided Focal Laser Ablation in Prostate Cancer

We are proud to release a detailed video animation of the minimally invasive, fusion-guided, focal laser ablation (FLA) of a prostate tumor using the TRANBERG™ Thermal Therapy System.

Read more

Sign up for our

Make sure you get all the exciting information about CLS’ progress on an ongoing basis.

*All the focal therapies report low rates of complications, and high rates of continence and erectile function preservation. Klotz et al. Curr Opin Urol. (2020).  

Welcome to Clinical Laserthermia Systems.

Please note that all our products and indications are not yet approved in all markets. Don’t hesitate to contact us for up-to-date market approvals in your area!

Please choose your country or region